First approved in 2000 for termination of pregnancies of ≤49 days' gestation, the indication for the oral antiprogestin mifepristone ( Mifeprex , and generics) was expanded in 2016 to include pregnancies of…
Med Lett Drugs Ther. 2023 Feb 20; 65(1670):31 doi:10.58347/tml.2023.1670c
First approved in 2000 for termination of pregnancies of ≤49 days' gestation, the indication for the oral antiprogestin mifepristone ( Mifeprex , and generics) was expanded in 2016 to include pregnancies of up to 10 weeks' gestation. A single 200-mg oral dose of mifepristone followed 24-48 hours later by a single 800-mcg buccal dose of the prostaglandin analog misoprostol terminates early intrauterine pregnancies in about 95% of women.
The FDA has removed the requirement that mifepristone ( Mifeprex , and generics), a progestin receptor antagonist approved for use in a regimen with the prostaglandin E1 analog misoprostol ( Cytotec , and…
Med Lett Drugs Ther. 2022 Jan 24; 64(1642):11
The FDA has removed the requirement that mifepristone ( Mifeprex , and generics), a progestin receptor antagonist approved for use in a regimen with the prostaglandin E1 analog misoprostol ( Cytotec , and generics) for medical termination of pregnancy, must be dispensed in person to the patient.
The FDA has approved osilodrostat ( Isturisa – Recordati), a cortisol synthesis inhibitor, for oral treatment of adults with Cushing's disease when surgical resection of the pituitary adenoma is not an…
Med Lett Drugs Ther. 2021 Feb 8; 63(1617):21-3
The FDA has approved osilodrostat ( Isturisa – Recordati), a cortisol synthesis inhibitor, for oral treatment of adults with Cushing's disease when surgical resection of the pituitary adenoma is not an option or has not been curative. Osilodrostat is the first cortisol synthesis inhibitor to be approved in the US for this indication. Other oral steroidogenesis inhibitors such as ketoconazole and metyrapone have been used off-label for this indication for many years.
The FDA has approved several significant changes in the labeling of mifepristone ( Mifeprex – Danco), an oral antiprogestin that has been used in the US for more than 15 years for termination of intrauterine…
Med Lett Drugs Ther. 2016 Apr 25; 58(1493):55-6
The FDA has approved several significant changes in the labeling of mifepristone ( Mifeprex – Danco), an oral antiprogestin that has been used in the US for more than 15 years for termination of intrauterine pregnancy. It has generally been used with the prostaglandin analog misoprostol ( Cytotec , and generics).